Lv3
360 积分 2024-01-28 加入
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
2天前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
2天前
已完结
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial
9天前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
22天前
已完结
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
1个月前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
2个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
2个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
NSCLC: Five trials to watch
3个月前
已完结
皖公网安备34019202002308
